|
MRI-Guided Radiotherapy for Prostate Cancer
Untitled Document
Name of the Trial
Phase I Study of MRI-Guided Intensity-Modulated External-Beam Radiotherapy
in Patients With Prostate Cancer (NCI-05-C-0191). See the protocol
summary.
Principal Investigator
Dr. Anurag Singh, NCI Center for Cancer Research.
 |
Dr. Anurag Singh
Principal Investigator |
Why This Trial Is Important
An estimated 234,460 American men will be diagnosed with prostate cancer in
2006. Many of these men will undergo external-beam radiation therapy to treat
their cancer.
In this study, doctors will use a new method called intensity-modulated external-beam
radiation therapy (IMRT) to treat men with
localized prostate cancer. Patients
will undergo a
magnetic resonance imaging (MRI) procedure, and doctors will
use the resulting images to pinpoint areas of the prostate containing cancer
cells. The presence of cancer in these areas will be confirmed with biopsies.
Doctors will then treat the areas identified as cancerous with higher doses
of radiation, while delivering a standard dose of radiation to the rest of the
prostate and surrounding normal tissue.
"When treating prostate cancer, higher radiation doses have produced better
outcomes," said Dr. Singh. "This trial is an attempt to use IMRT and
MRI imaging, confirmed by MRI-guided biopsy, to direct much higher doses of
radiation to those areas of the prostate containing tumor cells. The remainder
of the prostate will receive standard radiation doses. This may allow us to
more effectively treat the tumor without increasing toxicity to normal tissue."
With this
phase I trial, researchers will study the side effects and determine
the best dose of MRI-guided radiation therapy for treating patients with prostate
cancer.
Who Can Join This Trial
Researchers will recruit up to 36 patients aged 18 to 89 with a confirmed diagnosis
of prostate adenocarcinoma that has not spread to other parts of the body. See
the list
of eligibility criteria.
Study Site and Contact Information
The study is taking place at the NIH Clinical Center in Bethesda, Md. For more
information about this trial, call the NCI Clinical Studies Support Center toll-free
at 1-888-NCI-1937. This call is confidential.
 Back to Top |
